Mumbai, April 30, 2024. Sanofi India Limited has launched its’ new diabetes drug Soliqua® after having received the marketing authorization from the Central Drugs Standard Control Organization (CDSCO) earlier last year. Soliqua® is indicated as treatment in adults with obesity and type 2 diabetes mellitus, to improve glycemic control as an adjunct to diet and exercise, in those who are insufficiently controlled on oral or injectable therapies.

Living with type 2 diabetes could get complicated and burdensome. A large category of patients on multiple medications have to deal with weight gain, hypoglycemia and multiple injection pricks, even as they struggle to keep their blood sugar under control. The need of the hour is to help them reach and maintain optimal glycemic (blood sugar) control, keeping such worries at bay. Soliqua® simplifies these complexities by offering patients a sustained blood-sugar control, all day, in a simple, once-daily injection that can seamlessly fit into their lifestyle and help them break through the complexity of their diabetes management.

Cyrus Aibara

Head – Diabetes Business Unit, Sanofi (India)

“Over 100 million Indians[1] are living with type 2 diabetes and its complexities. Of these, >60% people are living with uncontrolled[2] blood sugar levels and have a higher risk of developing complications, despite being on treatment including multiple OADs (oral anti-diabetics) over a long period of time. The inclusion of Soliqua® to our comprehensive diabetes portfolio (orals and injectables) eases therapy initiation, which helps those prescribed, keep their blood sugar in control more effectively.”  

Dr. Shalini Menon

Country Medical Lead, Sanofi (India)

“Despite the advances in diabetes care, many people living with type 2 diabetes are unable to reach their sugar goals. Fear of hypoglycemia, weight gain and multiple injections can be barriers to effective treatment with insulins. In clinical trials, the combination injectable Soliqua® has demonstrated effective sugar control, without weight gain and with lower risk of hypoglycemia, compared to twice daily premix insulins.”

Soliqua® is a once-daily injectable combination drug containing insulin glargine 100 Units/ml, which is a long-acting basal insulin and lixisenatide, a GLP-1 receptor agonist. This global innovation is now accessible at a nominal therapy cost of INR 1850 per pen, enabling wider access to patients living with type 2 diabetes mellitus.

Sanofi – in India for India

As Sanofi India, we are in a great place to make a difference. Present in India for nearly seven decades, we have earned the trust of our customers and stakeholders for our commitment to promoting health. As we chase the miracles of science to improve people’s lives, we continue to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building. 

Our India Charitable Access Program (InCAP) is the country’s longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. We conduct clinical trials here so that India can have quicker access to the latest from our global pipeline. Our world-class manufacturing site in Goa produces for people in India and 60+ other countries. Sanofi has located one of its four global talent hubs in Hyderabad, India, from where wide range of services are provided globally.

Recognized by the ‘Top® Employers Institute’ – a global authority that honours excellence in people practices – for 5 years in a row (since 2019), our local entities include Sanofi India Limited (SIL - listed entity) and Sanofi Healthcare India Pvt. Ltd. (SHIPL).

Visit us at www.sanofi.in and www.sanofiindialtd.com, or connect with us on LinkedIn and Twitter.

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

[1] https://www.thelancet.com/journals/landia/article/PIIS2213-8587(23)00119-5/fulltext

[2] LANDMARC study final publication: Das AK, Kalra S, Joshi S, Mithal A, Kumar KMP, Unnikrishnan AG, Thacker H, Sethi B, Chowdhury S, Sugumaran A, Satpathy A, Gadekar A, Menon SK, Neogi R, Chodankar D, Trivedi C, Wangnoo SK, Zargar AH, Rais N; LANDMARC study group. The LongitudinAl Nationwide stuDy on Management And Real-world outComes of diabetes in India over 3 years (LANDMARC trial). Endocrinol Diabetes Metab. 2023 Sep;6(5):e422.